home / stock / acer / acer news

ACER News and Press, Acer Therapeutics Inc. From 05/09/22

Stock Information
Company Name: Acer Therapeutics Inc.
Stock Symbol: ACER
Market: NASDAQ
Website: acertx.com
Menu
ACER ACER Quote ACER Short ACER News ACER Articles ACER Message Board
Get ACER Alerts

News, Short Squeeze, Breakout and More Instantly...
ACER - Acer Therapeutics Announces Agreement with FDA on Special Protocol Assessment for its Phase 3 EDSIVO(TM) (celiprolol) Trial in Vascular Ehlers-Danlos Syndrome Patients

NEWTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced it ...
ACER - Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference

NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / May 6, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF, OTCQB:RLFTF, RLFTY) ("Relief"), today announced the presentation of data evaluating the bioavailability, bioeq...

ACER - Acer Therapeutics to Participate in H.C. Wainwright Global Investment Conference

NEWTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced tha...

ACER - Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

NEWTON, Mass. and GENEVA, April 12, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), today announced the presentation of data evaluati...
ACER - Acer, Relief report data showing bioequivalence of ACER-001 versus reference drug

Acer Therapeutics (NASDAQ:ACER) and Relief Therapeutics (OTCQB:RLFTF) said data from two phase 1 studies showed that taste-masked sodium phenylbutyrate (ACER-001) was bioequivalent to sodium phenylbutyrate (BUPHENYL(R)) powder under both fed and fasting conditions. The company has f...

ACER - Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting

NEWTON, MA and GENEVA, SWITZERLAND / ACCESSWIRE / April 12, 2022 / Acer Therapeutics Inc. (NASDAQ:ACER) ("Acer") and its collaboration partner, Relief Therapeutics Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), today announced the presentation of data evaluating the bioavailabili...

ACER - Shares of Acer Therapeutics Inc. (ACER) Rise to a New 52-Week High

Acer Therapeutics Inc. (NASDAQ:ACER) traded today at a new 52-week high of $3.72. This new high was reached on above average trading volume as 1.7 million shares traded hands, while the average 30-day volume is approximately 79,000 shares. Acer Therapeutics Inc operates as a pharmaceutic...
ACER - Protalix, Biophytis top healthcare gainers; while Curis, Longeveron lead losers' pack

Gainers: Protalix BioTherapeutics (PLX) +70%. Biophytis (BPTS) +21%. Clovis Oncology (CLVS) +13%. IN8bio (INAB) +13%. Acer Therapeutics (ACER) +12%. Losers: Curis (CRIS) -39%. Longeveron (LGVN) -15%. Bioventus (BVS) -14%. Clever Leaves (CLVR) -8%. NanoV...

ACER - Acer gains on FDA's Breakthrough status for Edsivo in genetic disorder

Clinical-stage pharma company, Acer Therapeutics (NASDAQ:ACER) has added ~27% in the pre-market Monday after announcing that the U.S. Food and Drug Administration (FDA) granted the Breakthrough Therapy designation for experimental therapy, celiprolol. The Breakthrough designation fo...

ACER - Acer Therapeutics' EDSIVO(TM) (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome

NEWTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced t...
Previous 10 Next 10